专利检索 ap:("Merck Frosst Canada Ltd.") AND inv:"TRANMER, Geoffrey, K." 第 1 页

1.

发明公开
SUBSTITUTED FUSED PYRIMIDINES AS ANTAGONISTS OF GPR105 ACTIVITY 审中-公开
标题翻译：取代的稠合嘧啶，其GPR105活性拮抗剂

公开(公告)号：EP2170883A1

公开(公告)日：2010-04-07

申请号：EP08772860.6

申请日：2008-06-26

申请人： Merck Frosst Canada Ltd.

发明人： GUAY, Daniel , BEAULIEU, Christian , BELLEY, Michel , CRANE, Sheldon, N. , DE LUCA, Jeancarlo , FORTIN, Rejean , GAREAU, Yves , LI, Lianhai , THERIEN, Michel , TRANMER, Geoffrey, K. , TRUONG, Vouy, Linh , WANG, Zhaoyin

IPC分类号： C07D471/04 , A61K31/519 , A61P3/00

CPC分类号： C07D471/04

摘要： Fused pyrimidine compounds of structural formula (I) are effective as antagonists of the biological activity of the GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and Metabolic Syndrome.

2.

发明公开
SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY 审中-公开
标题翻译：取代的2-NAPHTOESÄURENAS GPR105活性拮抗剂

公开(公告)号：EP2229373A1

公开(公告)日：2010-09-22

申请号：EP08856275.6

申请日：2008-12-01

申请人： Merck Frosst Canada Ltd.

发明人： BELLEY, Michel , DESCHENES, Denis , FORTIN, Rejean , FOURNIER, Jean-Francois , GAGNE, Sebastien , GAREAU, Yves , GAUTHIER, Jacques, Yves , LI, Lianhai , ROBICHAUD, Joel , THERIEN, Michel , TRANMER, Geoffrey, K. , WANG, Zhaoyin

IPC分类号： C07D333/24 , A61K31/192 , A61K31/381 , A61P3/04 , A61P3/10 , C07C65/11 , C07C65/24 , C07C63/36 , C07C69/76 , C07D317/60 , C07D249/08 , C07D211/34 , C07C317/44 , C07C323/62 , C07C65/30 , C07C65/34 , C07D211/52 , C07D333/34

CPC分类号： C07D211/34 , C07C65/24 , C07C65/30 , C07C65/40 , C07C69/76 , C07C69/94 , C07C317/44 , C07C317/46 , C07C323/62 , C07D211/52 , C07D249/08 , C07D317/60 , C07D333/16 , C07D333/24 , C07D333/34 , C07D487/04

摘要： Substituted 2-naphthoic acids of structural formula I are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome.